Patent intelligence · US
US 8569351
Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity
Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activi…
Patent details — US 8569351
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 29, 2013
- Expiration
- Oct 24, 2033
- Applicant
- Theravance, Inc.
- Claims
- 3
- CPC classes
- A61K, A61K31/415, A61K31/4164, A61K31/417
Quick answer
US 8569351 (Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity) is held by Theravance, Inc.. Status: granted. Granted Oct 29, 2013. Expires Oct 24, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Theravance, Inc.
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K31/415, A61K31/4164, A61K31/417, A61K31/4188, A61K31/4196
More from Theravance, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384761
Imidazolo indazole compounds as JAK inhibitors
granted -
US 12358931
3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
granted -
US 12351561
Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
granted -
US 12285417
Methods for treating chronic obstructive pulmonary disease
granted -
US 12258316
Biphenyl compounds useful as muscarinic receptor antagonists
granted -
US 12239638
Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
granted -
US 12172994
Pyrimidine compound as JAK kinase inhibitor
granted -
US 12122773
Crystalline hydrate of a JAK inhibitor compound
granted
Frequently asked questions
What is US patent 8569351?
US 8569351 (Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity) is held by Theravance, Inc.. Status: granted. Granted Oct 29, 2013. Expires Oct 24, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8569351?
Theravance, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 635 pharmaceutical patents for this assignee.
When does US 8569351 expire?
Our index shows an expiration date of Oct 24, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.